Suppr超能文献

影响十一酸睾酮油注射液肌肉注射后疼痛时间进程的因素。

Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate.

机构信息

Andrology Department, Concord Hospital & ANZAC Research Institute, Sydney, NSW, Australia.

出版信息

Asian J Androl. 2010 Mar;12(2):227-33. doi: 10.1038/aja.2010.1. Epub 2010 Feb 1.

Abstract

Pain following depot intramuscular (IM) injection of oil vehicle-based drugs has been little studied. This study aimed to determine prospectively the prevalence, determinants, severity and functional consequences of pain during the week after IM injection of 1 000 mg testosterone undecanoate (TU) in a 4-mL castor oil vehicle. Androgen-deficient men receiving regular T replacement therapy at an academic andrology clinic were recruited to report pain scores using a coloured visual linear analogue scale at seven times over the first day and daily for a week after a deep IM gluteal injection. The time course and covariables influencing pain scores were analysed by mixed model analysis of variance (ANOVA). Following 168 injections in 125 men, pain was reported by 80% of men, peaking immediately after injection, reaching only moderate severity, lasting 1-2 days and returning to baseline by day 4. The pain required little analgesic use and produced minimal interference in daily activities. The time course of pain scores was reproducible in the 43 men who underwent two consecutive injections. Pain was more severe in men who had an earlier painful injection, but less severe in older and more obese men. There were negligible differences in post-injection pain experience between experienced nurses administering injections. Deep IM gluteal injection of depot TU in 4-mL castor oil is well tolerated and post-injection pain is influenced by earlier painful injection experience, as well as age and obesity.

摘要

肌肉内(IM)注射油基药物后出现疼痛的问题研究较少。本研究旨在前瞻性确定 1000mg 十一酸睾酮(TU)以 4ml 蓖麻油为载体深部肌内注射后一周内疼痛的发生率、决定因素、严重程度和对功能的影响。在学术男科诊所接受常规睾酮替代治疗的雄激素缺乏男性,在深部臀部 IM 注射后第一天的 7 次和每天一次使用彩色视觉线性模拟量表报告疼痛评分。采用混合模型方差分析(ANOVA)分析疼痛评分的时间过程和协变量。在 125 名男性中进行了 168 次注射后,80%的男性报告出现疼痛,疼痛在注射后立即达到高峰,程度仅为中度,持续 1-2 天,第 4 天恢复基线。疼痛需要很少的镇痛药治疗,对日常活动的干扰极小。43 名连续接受两次注射的男性的疼痛评分时间过程具有可重复性。先前有过疼痛注射经历的男性疼痛更严重,但年龄较大和肥胖的男性疼痛程度较轻。经验丰富的护士进行注射时,注射后疼痛体验差异可以忽略不计。以 4ml 蓖麻油为载体深部肌内注射 TU 耐受性良好,注射后疼痛受先前疼痛注射经历以及年龄和肥胖的影响。

相似文献

1
Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate.
Asian J Androl. 2010 Mar;12(2):227-33. doi: 10.1038/aja.2010.1. Epub 2010 Feb 1.
2
Tolerability of intramuscular injections of testosterone ester in oil vehicle.
Hum Reprod. 1995 Apr;10(4):862-5. doi: 10.1093/oxfordjournals.humrep.a136051.
3
Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.
J Endocr Soc. 2019 Jun 28;3(8):1531-1540. doi: 10.1210/js.2019-00134. eCollection 2019 Aug 1.
7
Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Clin Endocrinol (Oxf). 1999 Dec;51(6):757-63. doi: 10.1046/j.1365-2265.1999.00881.x.

引用本文的文献

2
Biodegradable Long-Acting Injectables: Platform Technology and Industrial Challenges.
Handb Exp Pharmacol. 2024;284:133-150. doi: 10.1007/164_2023_651.
3
Expert Opinion on the Diagnosis and Management of Male Hypogonadism in India.
Int J Endocrinol. 2023 Feb 22;2023:4408697. doi: 10.1155/2023/4408697. eCollection 2023.
4
Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review.
Int J Impot Res. 2023 Aug;35(5):439-446. doi: 10.1038/s41443-022-00585-1. Epub 2022 May 24.
5
Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option.
J Clin Endocrinol Metab. 2022 Feb 17;107(3):614-626. doi: 10.1210/clinem/dgab772.
6
8
Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis.
Sex Med. 2020 Jun;8(2):237-242. doi: 10.1016/j.esxm.2020.01.009. Epub 2020 Mar 14.
9
Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02090-19.
10
Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.
J Endocr Soc. 2019 Jun 28;3(8):1531-1540. doi: 10.1210/js.2019-00134. eCollection 2019 Aug 1.

本文引用的文献

2
Pain and aging: the emergence of a new subfield of pain research.
J Pain. 2009 Apr;10(4):343-53. doi: 10.1016/j.jpain.2008.10.013.
3
Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men.
J Clin Endocrinol Metab. 2009 Jun;94(6):1910-5. doi: 10.1210/jc.2008-1846. Epub 2009 Mar 17.
5
On the origin of sensory impairment and altered pain perception in Prader-Willi syndrome: a neurophysiological study.
Eur J Pain. 2009 Sep;13(8):829-35. doi: 10.1016/j.ejpain.2008.09.011. Epub 2008 Nov 4.
6
Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.
J Sex Med. 2008 Oct;5(10):2442-53. doi: 10.1111/j.1743-6109.2008.00909.x. Epub 2008 Jul 1.
7
Male hormonal contraception: a double-blind, placebo-controlled study.
J Clin Endocrinol Metab. 2008 Jul;93(7):2572-80. doi: 10.1210/jc.2008-0265. Epub 2008 Apr 15.
10
More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Asian J Androl. 2007 May;9(3):291-7. doi: 10.1111/j.1745-7262.2007.00275.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验